Valuation : Geron Corporation

Market Cap 951M 820M 772M 703M 1.32B 90.24B 1.33B 9.12B 3.55B 45.9B 3.57B 3.49B 152B P/E 2026 *
-35.2x
P/E 2027 * 21.8x
Enterprise Value 951M 820M 772M 703M 1.32B 90.24B 1.33B 9.12B 3.55B 45.9B 3.57B 3.49B 152B EV / Sales 2026 *
4.02x
EV / Sales 2027 * 2.78x
Free-Float
99.92%
Yield 2026 *
-
Yield 2027 * -
1 day-0.67%
1 week-4.52%
Current month-0.67%
1 month+14.73%
3 months+22.31%
6 months-11.90%
Current year+12.12%
1 week 1.45
Extreme 1.45
1.56
1 month 1.24
Extreme 1.24
1.65
Current year 1.08
Extreme 1.08
2.01
1 year 1.04
Extreme 1.04
2.01
3 years 1.04
Extreme 1.04
5.34
5 years 0.99
Extreme 0.9899
5.34
10 years 0.75
Extreme 0.75
6.99
Manager TitleAgeSince
Chief Executive Officer 54 2025-08-06
Director of Finance/CFO 59 2023-09-24
Chief Tech/Sci/R&D Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 76 2010-05-20
Director/Board Member 72 2012-09-27
Director/Board Member 55 2019-03-25
Date Insider Type Main position Quantity % Market Cap. Importance
6/30/26 Free

Director

6,103 0.0010%
5/20/26 Free

Director

220,000 0.0343%
5/20/26 Free

Director

220,000 0.0343%
Change 5-day change 1-year change 3-year change Capi.($)
-0.67%-4.52%+5.71%-40.32% 951M
-0.25%-4.10%+38.38%+92.61% 68.21B
+1.21%+0.80%+46.29%+85.32% 64.25B
-0.25%-1.92%-10.72%+436.70% 26.54B
+0.33%-10.61%+1.95%-16.27% 25.61B
+1.18%-2.23%+30.87%-19.04% 19.88B
-6.09%-12.08%+226.11%+375.00% 17.13B
+0.29%-5.67%-1.52%+532.32% 14.93B
+4.12%+0.30%+52.03%+150.18% 14.1B
-0.24%+5.18%+23.04%+190.97% 12.45B
Average -0.04%-3.98%+41.21%+178.75% 26.4B
Weighted average by Cap. +0.15%-3.23%+41.08%+156.87%

Financials

2026 *2027 *
Net sales 236M 204M 192M 175M 328M 22.42B 330M 2.27B 882M 11.41B 887M 868M 37.82B 342M 295M 277M 253M 475M 32.45B 478M 3.28B 1.28B 16.51B 1.28B 1.26B 54.74B
Net income -27.18M -23.45M -22.06M -20.09M -37.78M -2.58B -37.99M -261M -101M -1.31B -102M -99.84M -4.35B 50.14M 43.25M 40.69M 37.07M 69.7M 4.76B 70.08M 481M 187M 2.42B 188M 184M 8.03B
Net Debt - -
Logo Geron Corporation
Geron Corporation is a commercial-stage biopharmaceutical company. The Company develops first-in-class telomerase inhibitor, RYTELO (imetelstat) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (lower-risk MDS), with transfusion-dependent (TD) anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). RYTELO is supported by the high unmet need in lower-risk MDS, including the observed benefit of RYTELO in difficult-to-treat subpopulations, such as patients with high transfusion burden and ring sideroblast negative (RS-) patients. It is also engaged in conducting a pivotal Phase III clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies.
Employees
258
Date Price Change Volume
26-09-01 $1.480 -0.67% 7,886,442
26-08-31 $1.490 -1.32% 7,247,301
26-08-28 $1.510 -1.31% 7,416,982
26-08-27 $1.530 0.00% 7,883,188
26-08-26 $1.530 -1.29% 9,123,636
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.480USD
Average target price
4.250USD
Spread / Average Target
+187.16%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GERN Stock